Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in Recurrent or Metastatic HNSCC
NCT03818061Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab and bevacizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Centre Léon Bérard. Primary endpoint: Overall Response Rate at 18 weeks. Started Mar 2019; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03818061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818061.